Medical technology company Wipro GE Healthcare announced an investment of over ₹8,000 crore in manufacturing output and local research and development over the next five years.
“As a part of this investment, the Wipro GE Healthcare Made in India PET CT Discovery IQ will be exported to 15 countries. Additionally, the Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured in India for the world,” the company said in a press release.
Wipro GE Healthcare said it was one of the first MedTech companies to ‘Make in India — for India and the world’ over the past three decades, investing upwards of over $4 billion in R&D and manufacturing output in India since inception.
The expanding strength of India in the healthcare sector was emphasized by Azim Premji, Chairman of Wipro GE Healthcare. With the launch of Made in India, the manufacturing sector in the nation is expanding rapidly, enhancing India's position as the global center for medical technology. "This strategic investment is a testament to our vision for this sector.
Wipro GE Healthcare has been committed to this localization journey for over three decades," the spokesperson stated. India is a high-potential market with significant promise, as noted by GE HealthCare President and CEO Peter J. Arduini. He also reaffirmed the company's commitment to strengthening India's domestic MedTech manufacturing and research and development capabilities.
At the moment, Wipro GE Healthcare has four export-focused production facilities in Bengaluru, according to the business. With a little over ₹100 crore in investment, the most recent factory was created in March 2022 as part of the government's Production-Linked Incentive (PLI) initiative.